用户中心

资讯 > 英文资料文献

Lower Cost Medical Devices FDA Wants to Help

作者:Daniel R. Matlis, Axendia2009.05.11阅读 8885

  Can the U.S. FDA help medical device manufacturers reduce cost and increase quality? Medical device manufacturers are dealing with some of the most difficult challenges to ever face the industry. In an increasingly global environmentwww.cechina.cn, as competition intensifiesCONTROL ENGINEERING China版权所有, manufacturers must innovate and capitalize on new opportunities and expedite time to market.
  To deal with these imperatives, medical device organizations are working to:
  Reduce costs;
  Increase product quality;
  Meet stricter inte

rpretations of regulatory requirements;
  Increase the rate of product innovation;
  Raise product safety and effectiveness; and
  Decrease time-to-market and time-to-profit.
  These challenges are exacerbated by the organizational structure and technological state of many medical device manufacturers and their interactions with the U.S. Food and Drug Administration (FDA), part of the Department of Health and Human Services.
  For years, device manufacturers have sought transparency into production information, processes, and resources. Companies have looked for the ability to unlock the operational data to empower decision makers—from operators to plant managers and corporate executives—to make informed timely decisions.
  Economic and regulatory shifts are poised to catapult shop floor systems into a key role to meet these challenges.
  Historically控制工程网版权所有, the typical interaction between FDA and Medical Device manufacturers involved the creationCONTROL ENGINEERING China版权所有, printing, and review of volumes of paper documents. These documents may have been part of pre market approval (PMA), 510k applications, or reviewed onsite in the course of a Quality System Regulation (QSR-21 CFR Part 820) inspection.

FDA suggests that one product lifecycle ties to the next and that each point in the lifecycle connects to every other


  FDA suggests that one product lifecycle ties to the next and that each point in the lifecycle connects to every other; thereforewww.cechina.cn, information flow is critical. The model seeks to integrate the complete product lifecycle by providing a holistic view of the process.  In TPLC, product development is itera

标签:control,FDA,
版权声明:版权归控制工程网所有,转载请注明出处!

频道推荐

关于我们

控制工程网 & CONTROL ENGINEERING China 全球工业控制、自动化和仪器仪表领域的先锋媒体

CE全球

联系我们

商务及广告合作
任小姐(北京)                 夏小姐(上海)
电话:010-82053688      电话:18616877918
rendongxue@cechina.cn      xiashuxian@cechina.cn
新闻投稿:王小姐

关注我们的微信

关于我们 | 网站地图 | 联系我们
© 2003-2020    经营许可编号:京ICP证120335号
公安机关备案号:110102002318  服务热线:010-82053688